Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial ...

- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 ...

With all the excitement over the new immune-checkpoint inhibitor drugs in melanoma, many of which are not yet available, it's easy to overlook another immunotherapy — tumor infiltrating lymphocytes ...

In a meta-analysis of solid organ transplant recipients with advanced cancer taking immune checkpoint inhibitors, half of patients died and 1 in 5 experienced graft loss. In solid organ transplant ...

New data show cancer survival has reached a record high — nearly 70% of patients now live at least five years after diagnosis ...